

INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Guselkumab for treating moderately to severely active ulcerative colitis ID6237

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
 Janssen (guselkumab) 	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Bladder and Bowel Community	Board of Community Health Councils in
Bowel Cancer UK	Wales Pritich National Formulan/
Colostomy UKCrohn's and Colitis UK	British National FormularyCare Quality Commission
 GUTS UK 	 Care Quality Commission Department of Health - Northern Ireland
 IA: Ileostomy and Internal Pouch 	 Bepartment of Health - Northern reland Healthcare Improvement Scotland
Association	 Medicines and Healthcare products
IBDrelief	Regulatory Agency
 South Asian Health Foundation 	 National Association of Primary Care
Specialised Healthcare Alliance	 National Pharmacy Association
	NHS Confederation
Healthcare professional groups	Scottish Medicines Consortium
Association of Coloproctology for	 Scottish Society of Gastroenterology
Great Britain and Ireland	Welsh Government
 British Geriatrics Society 	Welsh Health Specialised Services
British Society of	Committee
Gastroenterology	
Primary Care Society for	Possible comparator companies
Gastroenterology	AbbVie (adalimumab, risankizumab,
Royal College of General	upadacitinib)
Practitioners	Amgen (adalimumab),
Royal College of NursingRoyal College of Pathologists	Biogen Biosimilars (adalimumab, infliximab),
 Royal College of Pathologists Royal College of Physicians 	Bristol-Myers Squibb Pharmaceuticals
 Royal Pharmaceutical Society 	(ozanimod) Colltrian Haalthaara LIK (adalimumah
 Royal Society of Medicine 	 Celltrion Healthcare UK (adalimumab, infliximab)
 UK Clinical Pharmacy 	 Eli Lilly (mirikisumab)
Association	 Frezenius, Kabi (adalimumab)
	 Galapagos Biotech (filgotinib)
<u>Others</u>	 Janssen-Cilag (ustekinumab)
Department of Health and Social	 Merck, Sharp and Dohme, UK (golimumab,
Care	infliximab)
Health Technology Wales (HTW)	Pfizer (etrasimod, infliximab, tofacitinib)

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active ulcerative colitis ID6237

Issue date: January 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
NHS England	 Sandoz (adalimumab, infliximab) Takeda UK (vedolizumab)
	Relevant research groups
	 Genomics England MRC Clinical Trials Unit National Institute for Health Research
	 <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active ulcerative colitis ID6237 Issue date: January 2025 © National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3



All non-company commentators are invited to nominate clinical or patient experts.